TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
NLS Pharmaceutics ( (NLSP) ) just unveiled an update.
On September 4, 2025, NLS Pharmaceutics and its merger partner Kadimastem announced the granting of a Hong Kong patent for a cell-selection and enrichment technology used in IsletRx, a stem cell-derived therapy candidate for insulin-dependent diabetes. This patent expands the intellectual property protection in Asia, complementing existing patents in Europe, the United States, and India, and supports the long-term strategy for IsletRx. The move is significant given Hong Kong’s role as a gateway to Mainland China and its substantial diabetes market, potentially impacting future clinical collaborations and commercialization efforts.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss-based biopharmaceutical company focused on developing innovative therapies for central nervous system disorders and related indications.
Average Trading Volume: 246,744
Technical Sentiment Signal: Sell
Current Market Cap: $7.41M
For detailed information about NLSP stock, go to TipRanks’ Stock Analysis page.